A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pembrolizumab (Primary) ; UV 1 (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Registrational
Sponsors Ultimovacs AS

22 Aug 2024 Status changed from active, no longer recruiting to completed.
11 Jun 2024 Results presented in an Ultimovacs AS Media Release.
12 Oct 2023 According to an Ultimovacs AS media release, the 4-year survival across both cohorts is expected to be announced in Q2 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com